Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.
The company’s pipeline encompasses multiple programs across various stages of development. Its lead asset, filgotinib—a selective JAK1 inhibitor—was developed in collaboration with Gilead Sciences for the treatment of rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease. In addition to filgotinib, Galapagos is advancing compounds targeting osteoarthritis, idiopathic pulmonary fibrosis and APOL1-mediated kidney disease, with several candidates currently in Phase 2 and Phase 3 clinical trials.
Galapagos maintains strategic partnerships and licensing agreements to extend its research capabilities and global reach. In 2019, the company entered into a collaboration and license agreement with Gilead Sciences, which included an equity investment and options on select pipeline programs. Galapagos also collaborates with Servier, a French pharmaceutical company, to co-develop and commercialize multiple anti-inflammatory programs in Europe and other territories. Its clinical study sites and research facilities span Europe and the United States, reflecting a commitment to conducting trials and manufacturing operations in key markets.
Leadership at Galapagos is headed by Chief Executive Officer Paul Stoffels, who joined the company in 2020 after serving as Chief Scientific Officer at Johnson & Johnson. Under Stoffels’ direction, Galapagos has emphasized precision medicine and accelerated development timelines. The company employs a multidisciplinary team of scientists, clinicians and regulatory specialists, reinforcing its mission to translate genetic insights into first-in-class and best-in-class therapies for patients worldwide.
